Bristol Earns Prestigious Tessa Jowell Brain Cancer Excellence Award in Bristol 2026

Key Points

• National Recognition: Bristol, together with the Somerset, Wiltshire, Avon and Gloucestershire Neuro-Oncology Network (with the University of Bristol), has won the honor of being recognized as a Tessa Jowell Centre of Excellence for Adults.
• National Extension: Bristol is one of six neuro-oncology centers to have received recognition as part of the latest cohort, thus taking the total number of Centers of Excellence for Adults recognized nationwide to 20.
• Improved Scope: With this extension, two-thirds of the UK population will be covered by the catchment area of a Tessa Jowell Centre of Excellence for Adults, thereby improving access from a geographical disparity standpoint.
• Formal Presentation: The recognition will officially be announced on October 15, at the Royal Society in London, by Yvette Cooper, Secretary of State for Health and Social Care, and Professor Peter Johnson, the National Clinical Director for Cancer at NHS England.
• Strict Assessment: The designation was granted after a detailed evaluation process led by experts including input provided by patients through The Brain Tumour Charity.
• Areas Commended: The expert panel praised Bristol for its surgical innovation, cutting-edge neuropathology and tissue bank facility, chemotherapy treatment, and nurse-coordinated patient care.

Bristol (Bristol Express News) October 15, 2026 – Bristol has officially been designated a Tessa Jowell Centre of Excellence for Adults, joining a network of leading NHS facilities providing high-calibre care and research access for patients diagnosed with brain tumours.

What Is the Significance of the New Tessa Jowell Centre Designation?

As reported by Mirage News, Bristol is one of six regional NHS neuro-oncology hubs awarded the designation, bringing the UK total to 20 accredited adult centres. This milestone ensures that two-thirds of the British population now reside within the immediate catchment area of a recognized Centre of Excellence, marking a significant advancement in equitable, high-standard healthcare access.

The formal conferral of the designation takes place on the afternoon of 15 October at a dedicated event at the Royal Society in London. The announcement will be confirmed by Yvette Cooper, Secretary of State for Health and Social Care, alongside Professor Peter Johnson, Professor of Medical Oncology at the University of Southampton, National Clinical Director for Cancer at NHS England, and Chair of the UK Office for Life Sciences cancer mission.

Despite advancements across broader oncology disciplines, aggressive brain tumours remain the leading cause of cancer-related mortality among children and adults under the age of 40 in the United Kingdom. Current clinical data indicates that survival rates for the most aggressive brain tumour classifications have seen minimal improvement in recent decades. Beyond mortality risks, patients regularly face severe physical, neurological, cognitive, and psychological burdens. In the absence of definitive curative therapies, establishing consistent clinical standards, specialized rehabilitation, and research integration remains critical.

How Was Bristol’s Neuro-Oncology Service Evaluated?

The designation was conferred following an exhaustive assessment process led by an independent panel of neuro-oncology experts, working alongside patient experience data compiled by The Brain Tumour Charity. The multidisciplinary evaluation reviewed surgical capabilities, pathology, clinical trial availability, nursing care, and patient-reported outcomes.

As detailed in the public release published by Mirage News, the assessment panel highlighted four primary pillars of excellence within the Bristol network:

• Surgical Innovation: An agile surgical team delivering timely, high-precision operative treatments.
• Advanced Neuropathology: Highly developed infrastructure in genomics, molecular diagnostic testing, and biobanking, supported by an active academic research portfolio.
• Systemic Therapy Infrastructure: A structured chemotherapy service designed to guide clear clinical decision-making and manage complex side effects effectively.
• Integrated Nursing & Care Coordination: Patient-centric care delivery overseen by a dedicated nursing staff coordinating treatment across expansive geographical boundaries.

What Did Key Healthcare Leaders Say About the Award?

In statements documented by Mirage News, leadership representatives from the Tessa Jowell Brain Cancer Mission (TJBCM) and local clinical teams commended the institutional effort required to attain the accreditation.

As reported by Mirage News, Nicky Huskens, Chief Executive of the Tessa Jowell Brain Cancer Mission, stated:

“Congratulations to the team at Bristol. This award is a testament to the hard work of an incredible team working above and beyond to deliver a world-class brain tumour service. Designation as a Centre of Excellence means more than just excellent care – it is a commitment to constantly improving, going further and faster for this patient group. We look forward to continued collaboration on our collective vision that every patient with a brain tumour benefits from excellent treatment, care and access to research – whoever they are, wherever they live.”

Emphasising the academic and research dimensions of the network, Kathreena Kurian, Professor of Neuropathology, Consultant Neuropathologist at Bristol NHS Foundation Trust (BFT), and Head of the Brain Tumour Research Centre at the University of Bristol, remarked:

“Achieving recognition as a Tessa Jowell Centre of Excellence is a tremendous honour for Bristol and a tribute to the dedication and collaboration of our multidisciplinary team. Above all, we are grateful to our patients and their families, whose trust, courage and experiences inspire everything we do. Together, we are committed to advancing research, improving diagnosis and treatment, and ensuring that adults with brain tumours have access to the best possible care and the latest scientific advances.”

Underlining the daily clinical operations across the regional network, Mr Venkat Iyer, Consultant Neurosurgeon and Neuro-Oncology Multidisciplinary Team Chair at the Bristol NHS Foundation Trust (BFT), noted:

“We are delighted to be recognised by the Tessa Jowell Brain Cancer Mission as a Centre of Excellence for brain tumours. We take great pride in providing a responsive, compassionate and comprehensive service for adults living with brain tumours across Bristol and the surrounding areas. This recognition reflects the passion, dedication, teamwork and kindness of our extended multidisciplinary team, who work tirelessly to ensure that every patient receives the very best care and support throughout their journey. We are incredibly grateful to our whole team, whose commitment to our patients and their families, and willingness to always go the extra mile, makes such a meaningful difference.”

Explore more Local Bristol News:

Why Did Pero’s Bridge Fail? Inspection Report Reveals Corrosion, Bristol 2026

Clifton Suspension Bridge Master Hails Major Refurbishment Completion in Bristol 2026

Which UK Centres Hold the Tessa Jowell Excellence Designation?

With six new designations joining the 14 awarded during previous review cycles in 2024, the full network of 20 Tessa Jowell Centres of Excellence for Adults across the UK now comprises:

What Is the Background of the Tessa Jowell Brain Cancer Mission?

The Tessa Jowell Brain Cancer Mission (TJBCM) was established following the advocacy of Dame Tessa Jowell, a former UK Cabinet Minister who was diagnosed with a glioblastoma in 2017. Following her diagnosis, Jowell used her platform in the House of Lords to campaign for improved research funding, accelerated access to adaptive clinical trials, and equal standards of care for brain cancer patients across the National Health Service.

Prior to the initiative, brain tumour clinical services across the UK experienced variable levels of resource allocation and service delivery, commonly referred to as a “postcode lottery.” Following Jowell’s death in May 2018, government bodies, charitable organisations, clinicians, and academic institutions formed the TJBCM to institutionalise higher clinical standards.

The Centre of Excellence designation program was created to evaluate NHS trusts systematically against detailed benchmarks encompassing surgical precision, clinical trial integration, genomic profiling, nurse-led coordination, and holistic palliative support. Centres awarded this status undergo periodic reassessment to maintain high service standards and drive ongoing continuous improvement.

How Will This Development Affect NHS Patients and the UK Healthcare Sector?

The designation of Bristol and its partner regional trusts as a Tessa Jowell Centre of Excellence is anticipated to produce measurable operational and patient-level effects across the South West of England and the broader NHS structure:

1. Enhanced Local Access to Advanced Clinical Trials:Patients residing in Bristol, Somerset, Wiltshire, Avon, and Gloucestershire will gain streamlined access to early-stage pharmaceutical trials, precision medicine protocols, and novel surgical techniques without requiring long-distance travel to London or other distant regional centres.
2. Standardisation of Patient Care Pathways:The inclusion of two-thirds of the UK population within accredited catchment areas is expected to narrow the historical variance in survival outcomes and treatment quality between different NHS trusts, providing consistent nurse-led coordination and faster diagnostic turnarounds.
3. Expanded Biobanking and Genomic Research Output:With Bristol’s strength in tissue banking and genomics specifically cited in the award evaluation, increased clinical volume through the network will expand high-quality tissue sample repositories, supporting national research into aggressive tumour biologies and targeted molecular therapies.
4. Resource and Recruitment Advantages:Achieving recognized Centre of Excellence status strengthens local institutional prestige, assisting participating NHS trusts and the University of Bristol in attracting specialist neuro-oncologists, clinical nurse specialists, and competitive research funding.